Bypassing glycosylation

Engineering aglycosylated full-length IgG antibodies for human therapy

Sang Taek Jung, Tae Hyun Kang, William Kelton, George Georgiou

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

In recent years a number of aglycosylated therapeutic antibodies have entered the clinic. The clinical evaluation of these antibodies has served to dispel concerns that the absence of the ubiquitous N297 glycan in the Fc of IgG might result in immunogenicity, poor in vivo stability or unfavorable pharmacokinetics. Importantly, recent studies have now demonstrated that aglycosylated antibodies can be engineered to display novel effector functions and mechanisms of action that do not appear to be possible with their glycosylated counterparts. Moreover, the ability to manufacture aglycosylated antibodies in lower eukaryotes or in bacteria provides significant bioprocessing advantages in terms of shorter bioprocess development and running times and by completely bypassing the problems associated with the glycan heterogeneity of conventional antibodies. These advantages are poised to catapult aglycosylated antibodies to the forefront of protein therapeutics.

Original languageEnglish
Pages (from-to)858-867
Number of pages10
JournalCurrent Opinion in Biotechnology
Volume22
Issue number6
DOIs
Publication statusPublished - 2011 Dec 1
Externally publishedYes

Fingerprint

Glycosylation
Antibodies
Immunoglobulin G
Polysaccharides
Therapeutics
Pharmacokinetics
Eukaryota
Running
Bacteria
Proteins

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Bypassing glycosylation : Engineering aglycosylated full-length IgG antibodies for human therapy. / Jung, Sang Taek; Kang, Tae Hyun; Kelton, William; Georgiou, George.

In: Current Opinion in Biotechnology, Vol. 22, No. 6, 01.12.2011, p. 858-867.

Research output: Contribution to journalReview article

Jung, Sang Taek ; Kang, Tae Hyun ; Kelton, William ; Georgiou, George. / Bypassing glycosylation : Engineering aglycosylated full-length IgG antibodies for human therapy. In: Current Opinion in Biotechnology. 2011 ; Vol. 22, No. 6. pp. 858-867.
@article{fa8feb13f53940c0a7bb8adc4e8e288f,
title = "Bypassing glycosylation: Engineering aglycosylated full-length IgG antibodies for human therapy",
abstract = "In recent years a number of aglycosylated therapeutic antibodies have entered the clinic. The clinical evaluation of these antibodies has served to dispel concerns that the absence of the ubiquitous N297 glycan in the Fc of IgG might result in immunogenicity, poor in vivo stability or unfavorable pharmacokinetics. Importantly, recent studies have now demonstrated that aglycosylated antibodies can be engineered to display novel effector functions and mechanisms of action that do not appear to be possible with their glycosylated counterparts. Moreover, the ability to manufacture aglycosylated antibodies in lower eukaryotes or in bacteria provides significant bioprocessing advantages in terms of shorter bioprocess development and running times and by completely bypassing the problems associated with the glycan heterogeneity of conventional antibodies. These advantages are poised to catapult aglycosylated antibodies to the forefront of protein therapeutics.",
author = "Jung, {Sang Taek} and Kang, {Tae Hyun} and William Kelton and George Georgiou",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.copbio.2011.03.002",
language = "English",
volume = "22",
pages = "858--867",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Bypassing glycosylation

T2 - Engineering aglycosylated full-length IgG antibodies for human therapy

AU - Jung, Sang Taek

AU - Kang, Tae Hyun

AU - Kelton, William

AU - Georgiou, George

PY - 2011/12/1

Y1 - 2011/12/1

N2 - In recent years a number of aglycosylated therapeutic antibodies have entered the clinic. The clinical evaluation of these antibodies has served to dispel concerns that the absence of the ubiquitous N297 glycan in the Fc of IgG might result in immunogenicity, poor in vivo stability or unfavorable pharmacokinetics. Importantly, recent studies have now demonstrated that aglycosylated antibodies can be engineered to display novel effector functions and mechanisms of action that do not appear to be possible with their glycosylated counterparts. Moreover, the ability to manufacture aglycosylated antibodies in lower eukaryotes or in bacteria provides significant bioprocessing advantages in terms of shorter bioprocess development and running times and by completely bypassing the problems associated with the glycan heterogeneity of conventional antibodies. These advantages are poised to catapult aglycosylated antibodies to the forefront of protein therapeutics.

AB - In recent years a number of aglycosylated therapeutic antibodies have entered the clinic. The clinical evaluation of these antibodies has served to dispel concerns that the absence of the ubiquitous N297 glycan in the Fc of IgG might result in immunogenicity, poor in vivo stability or unfavorable pharmacokinetics. Importantly, recent studies have now demonstrated that aglycosylated antibodies can be engineered to display novel effector functions and mechanisms of action that do not appear to be possible with their glycosylated counterparts. Moreover, the ability to manufacture aglycosylated antibodies in lower eukaryotes or in bacteria provides significant bioprocessing advantages in terms of shorter bioprocess development and running times and by completely bypassing the problems associated with the glycan heterogeneity of conventional antibodies. These advantages are poised to catapult aglycosylated antibodies to the forefront of protein therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=80052622662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052622662&partnerID=8YFLogxK

U2 - 10.1016/j.copbio.2011.03.002

DO - 10.1016/j.copbio.2011.03.002

M3 - Review article

VL - 22

SP - 858

EP - 867

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

IS - 6

ER -